{
    "clinical_study": {
        "@rank": "62176", 
        "acronym": "M13DAP", 
        "arm_group": {
            "arm_group_label": "Dacomitinib + PD-0325901", 
            "arm_group_type": "Experimental", 
            "description": "Dacomitinib: oral tablets PD-0325901: oral capsules"
        }, 
        "brief_summary": {
            "textblock": "This is a phase I/II multi-center open-label proof of concept study, consisting of two\n      parts. Part A of this study is designed to identify the recommended phase 2 dose (RP2D) of\n      the combination regimen of dacomitinib plus PD-0325901 in patients with advanced KRAS mutant\n      (KRASm) colorectal cancer (CRC), non-small cell lung cancer (NSCLC), or pancreatic cancer.\n      Part B is designed to perform a randomized comparison of the combination of dacomitinib and\n      PD-0325901 versus standard of care therapy in patients with advanced KRASm CRC, NSCLC, or\n      pancreatic cancer. It is hypothesized that with this combination strategy the progression\n      free survival of patients with KRASm CRC, NSCLC or pancreatic cancer will be doubled."
        }, 
        "brief_title": "Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant Malignancies", 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histological or cytological proof of advanced colorectal cancer (CRC), non-small cell\n             lung cancer (NSCLC) or pancreatic cancer\n\n          -  Written documentation of KRAS (exon 2, 3 or 4) mutation\n\n          -  At least 18 years of age or older\n\n          -  Able and willing to give written informed consent\n\n          -  WHO performance status of 0, 1 or 2\n\n        Exclusion Criteria:\n\n          -  Symptomatic or untreated leptomeningeal disease\n\n          -  Symptomatic brain metastasis\n\n          -  Impairment of gastrointestinal function\n\n          -  Uncontrolled infectious disease\n\n          -  Left ventricular ejection fraction < 50%\n\n          -  Retinal degenerative disease or with history of uveitis, retinal vein occlusion or\n             retinal detachment\n\n        Other protocol-defined inclusion/exclusion criteria may apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "35", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02039336", 
            "org_study_id": "NL45985.031.13"
        }, 
        "intervention": [
            {
                "arm_group_label": "Dacomitinib + PD-0325901", 
                "intervention_name": "Dacomitinib", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dacomitinib + PD-0325901", 
                "intervention_name": "PD-0325901", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dacomitinib + PD-0325901", 
                "intervention_name": "Irinotecan", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dacomitinib + PD-0325901", 
                "intervention_name": "Docetaxel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Dacomitinib + PD-0325901", 
                "intervention_name": "Capecitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Irinotecan", 
                "Docetaxel", 
                "Capecitabine"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 15, 2014", 
        "location": [
            {
                "contact": {
                    "email": "j.slijkerman@nki.nl", 
                    "last_name": "JHM Schellens, MD, PhD", 
                    "phone": "+31 20 512 2446"
                }, 
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands", 
                        "zip": "1066CX"
                    }, 
                    "name": "The Netherlands Cancer Institute"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands", 
                        "zip": "3015CE"
                    }, 
                    "name": "Erasmus Medical Center Cancer Institute"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands", 
                        "zip": "3584CX"
                    }, 
                    "name": "University Medical Center Utrecht"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Advanced KRAS Mutation Positive Colorectal, Non-small Cell Lung and Pancreatic Cancer", 
        "overall_contact": {
            "email": "j.slijkerman@nki.nl", 
            "last_name": "Jan HM Schellens, MD, PhD", 
            "phone": "0031205122446"
        }, 
        "overall_official": [
            {
                "affiliation": "The Netherlands Cancer Institute", 
                "last_name": "JHM Schellens, MD, PhD", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Erasmus Medical Centre Cancer Institute", 
                "last_name": "FALM Eskens, PhD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "UMC Utrecht", 
                "last_name": "MPJK Lolkema, PhD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Studies (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Incidence rate of dose-limiting toxicities", 
                "safety_issue": "Yes", 
                "time_frame": "1.5 years"
            }, 
            {
                "measure": "Progression free survival", 
                "safety_issue": "No", 
                "time_frame": "2.5 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02039336"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence and severity of adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "2.5 years"
            }, 
            {
                "measure": "Plasma concentration", 
                "safety_issue": "No", 
                "time_frame": "2.5 years"
            }, 
            {
                "measure": "Overall response rate", 
                "safety_issue": "No", 
                "time_frame": "2.5 years"
            }, 
            {
                "measure": "Duration of response", 
                "safety_issue": "No", 
                "time_frame": "1.5 years"
            }, 
            {
                "measure": "Time to response", 
                "safety_issue": "No", 
                "time_frame": "2.5 years"
            }, 
            {
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "source": "The Netherlands Cancer Institute", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "The Netherlands Cancer Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}